Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023

Showcasing Scinai’s end-to-end cGMP Biologics CDMO services at booth 271

Pursuing partnerships for Scinai’s pipeline of novel VHH antibody-based therapies

JERUSALEM, Oct. 30, 2023 -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announces that it will be showcasing both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline at BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events, taking place Nov. 6 to 8 in Munich, Germany.

Members of the company’s executive leadership team will be available to meet with potential partners and clients of the company’s end-to-end biologics CDMO services at Scinai’s booth 271.

One-to-one meetings may be requested through the BIO partnering platform, accessible to participants after registration through https://informaconnect.com/bioeurope/. Interested parties are also welcome to contact Scinai directly through the information provided below.

Leveraging the company’s state-of-the-art manufacturing facility for biopharmaceutical products, Scinai’s CDMO offers biologic drugs process development and scale-up for protein-based drugs, analytical method development for QC testing and cGMP manufacturing including aseptic filling at FDA/EMA standards to pharmaceutical and biotech clients.

In parallel, Scinai’s in-house R&D program is focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. Development is currently centered on a pipeline of innovative nanosized VHH antibody (NanoAb) therapies addressing diseases underserved by current monoclonal antibody treatments and with large and growing markets, such as psoriasis, asthma, psoriatic arthritis, wet macular degeneration and COVID-19.

About Scinai Immunotherapeutics: Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com.

Company Contact: Joshua Phillipson | +972 8 930 2529 | joshua.phillipson@scinai.com 

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the timing of future preclinical clinical trials, and the therapeutic and commercial potential of NanoAbs. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to, the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European Investment Bank (EIB) may accelerate the loans under its finance contract with Scinai; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai’s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 17, 2023. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com